Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX Stock Report

Mkt Cap: US$1.8b

Recursion Pharmaceuticals Future Growth

How is Recursion Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-11.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:RXRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202510-379N/AN/A1
12/31/202485-260-279-2495
12/31/202371-230-230-2026
9/30/202229-247-134-100N/A
6/30/202218-234-113-78N/A
3/31/202213-212-75-50N/A
12/31/202110-186-198-159N/A
9/30/202110-147-129-89N/A
6/30/20219-124-106-75N/A
3/31/20216-99-84-58N/A
12/31/20204-87-52-45N/A
12/31/20192-62-61-57N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RXRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RXRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RXRX's revenue (14.2% per year) is forecast to grow faster than the US market (7.1% per year).

High Growth Revenue: RXRX's revenue (14.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RXRX is forecast to be unprofitable in 3 years.


Discover growth companies